Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

This study is testing a combination of three treatments — a targeted radiation therapy delivered directly to the liver (Y-90), an oral chemotherapy drug (capecitabine), and an immunotherapy drug (atezolizumab) — for people with colorectal cancer that has spread mainly to the liver and cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with colorectal cancer that has spread and is confirmed by biopsy - Your disease has spread mainly to the liver and cannot be surgically removed - You have tried at least 2 prior treatment regimens that did not work - The cancer takes up less than half of your liver - Your blood counts, kidney, and liver function are in acceptable ranges - You are 18 or older with a good performance status (able to care for yourself) **You may NOT be eligible if...** - Your cancer has spread widely beyond the liver - You have active autoimmune disease or are taking steroids for immune-related reasons - You have had a prior organ transplant - You have uncontrolled hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.